SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

CRMD

CorMedix, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor the Heron acquisition closing timeline and integration progress, as well as CMS reimbursement framework updates that could affect DefenCath pricing and utilization in 2027.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

CRMD drug pipeline →

rezafungin

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
Next catalyst
NDA filing · 2026

What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.84
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.72%
T+1 · $4.66
Vs SPY
−3.36%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $4.84entry
  2. T+1 · 4d ago −3.72%α −3.36% · $4.66
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix reported Q3 2026 consolidated revenue of $54.5M, above consensus of $52.8M, but GAAP net loss of $14.7M ($-0.19 per share) versus consensus EPS of $-0.11. Adjusted EBITDA was $3.1M. Revenue declined 48% YoY due to DefenCath's post-TDAPA pricing transition. The company maintained FY 2026 revenue guidance of $325-$345M and narrowed adjusted EBITDA guidance to $130-$140M. The pending Heron Therapeutics asset acquisition adds four commercial products and is expected to close in Q1 2027.

Key Financial Metrics

EPS
−$0.19
est −$0.11 · -72.7%
Revenue
$54.5M
est $52.8M · +3.2% · -47.7% YoY
Rating
in line
Guidance
$325M-$345M
maintained
Gross Margin
55%

Key Facts

  • Q3 2026 consolidated revenue $54.5M, above consensus $52.8M but down 48% YoY from $104.3M
  • GAAP net loss $14.7M ($-0.19 per share) vs consensus EPS $-0.11; prior year net income $108.6M
  • Adjusted EBITDA $3.1M, down from $71.9M in Q3 2025
  • DefenCath sales $17.2M, down from prior year due to post-TDAPA pricing transition
  • Remaining portfolio contributed $37.3M revenue and grant income
  • FY 2026 revenue guidance maintained at $325-$345M; adjusted EBITDA guidance narrowed to $130-$140M
  • Pending Heron asset acquisition for $145M cash plus 14.58M shares, funded by up to $150M term loan
  • Cash and short-term investments $355.2M at September 30, 2026

Financial Impact

Revenue $54.5M (consensus $52.8M), EPS $-0.19 (consensus $-0.11), adjusted EBITDA $3.1M

revenueepsadjusted EBITDAcash position

Segment Breakdown

SegmentRevenue
DefenCath$17.2M
Remaining portfolio$37.3M

Risk Factors

  • DefenCath revenue decline from post-TDAPA pricing pressure may persist
  • Heron acquisition integration and debt service costs could pressure margins
  • Suspended 2027 DefenCath guidance signals uncertainty in core product outlook
  • Pending FDA action on REZZAYO sNDA in Q1 2027 adds binary catalyst risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401467

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Viewing Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026